This whitepaper examines how manufacturing has become a gating factor in the product lifecycle, with a focus on the evolution of the embedded CDMO model. The discussion explores early-stage collaboration, long-term capacity reservations, dual-sourcing strategies, digital integration, and the regulatory implications of deeper sponsor-CDMO partnerships.
The US Food and Drug Administration has issued its final guidance outlining expectations for promotional labeling and advertising for biologics, biosimilars, and interchangeable biosimilars. The document aims to ensure that promotional communications across all media are accurate, non-misleading, and consistent with the approved product labeling.
Dr. Vinay Prasad has stepped down from his role as Director of the FDA’s Center for Biologics Evaluation and Research (CBER), less than three months after taking the post. His sudden resignation marks a significant leadership shift for the agency’s oversight of vaccines, cell therapies, and gene therapy products.
As the demand for cost-effective biologic therapies continues to grow, biosimilars have emerged as a critical solution for improving patient access to life-saving treatments. These FDA-approved biologic alternatives closely resemble existing reference products and offer a more affordable option without compromising safety or efficacy.
A Pre-Biologics License Application (Pre-BLA) meeting is a critical milestone in the regulatory pathway for biologic products. This meeting is held between a biologic product sponsor and the FDA before the submission of a Biologics License Application (BLA). The primary goal is to discuss the forthcoming BLA submission, ensuring that it meets all regulatory requirements and addresses any potential issues that could delay the approval process.
In this blog, we delve into the BLA process to shed light on its intricacies and provide insights for biopharmaceutical innovators.
In this blog, we will delve into the intricacies of the BLA process, exploring its significance, key components, and the steps involved in bringing a biologic product to market.
In this blog post, we will delve into the essential aspects of the BLA process, shedding light on the steps involved and the significance of each stage.
Unlike traditional pharmaceutical or medical device products, combination products must satisfy multiple regulatory frameworks simultaneously, requiring close collaboration between quality, regulatory affairs, engineering, manufacturing, and clinical teams. As regulatory agencies continue to emphasize quality systems, risk management, human factors, and lifecycle oversight, organizations must adopt integrated compliance strategies to successfully bring these products to market.
Understanding the key inspection trends shaping FDA oversight in 2026 can help companies strengthen quality systems, improve operational effectiveness, and prepare for future regulatory interactions.